US/UK/Canada

Share

Pick a time period -
Tags ( Active)

NeoDynamics AB (publ) full-year report 2021

NeoNavia® is gaining ground Fourth quarter October-December 2021 · Revenues amounted to SEK 930 (3,382) thousand, of which SEK 0 (2,963) thousand capitalized costs and SEK 839 (0) thousand net sales, ie sales of finished products. · Loss after tax amounted to SEK -19,134 (-11,524) thousand. · Loss per share amounted to SEK -0.32 (-0.28). · Cash and cash equivalents amounted to SEK 24,710 (73,250) thousand. Full year January-December 2021 · Revenues amounted to SEK 2,085 (18,558) thousand, of which SEK 785 (17,104) thousand capitalized costs. · Loss after tax

Interim report Jan-June 2021

Clinics build experienceSecond Quarter 2021 · Revenue amounted to SEK 411 (6,263) thousand, of which SEK 383 (5,787) thousand were capitalized costs. · Loss after tax amounted to SEK-18,263 (-5,516) thousand. · Loss per share SEK -0.30 (-0.18). · Cash and cash equivalents amounted to SEK 48,339 (7,177) thousand. First half of 2021 · Revenues amounted to SEK 816 (12,531) thousand, of which SEK 762 (12,090) thousand capitalized costs. · Cash flow from operating activities amounted to SEK -23,999 (-13,107) thousand. · Profit after tax amounted to SEK -35,519 (-12,

NeoDynamics presents preclinical results today

Dr. Stefan Paepke presents an abstract on preclinical results with NeoDynamics’ innovative biopsy system NeoNavia at the St Gallen International Breast Cancer Conference 2021, which begins in Vienna today. The results show that tissue samples taken with all of NeoNavia’s three needle types provide significantly larger tissue samples than what today’s gold standard technologies achieve. The weight of the tissue samples taken with NeoNavia’s needles was 299 percent higher with the FlexiPulse needle than with today’s gold standard, 37 percent higher with CorePulse and 12 percent higher with

There are no items matching the current filter
There are no more items matching the current filter
Back to top